Relationship of Serum Glycemic Status with Serum Zinc Level in Type 2 Diabetes Mellitus.
Eva H,Akter Q S,Alam M K
Mymensingh medical journal : MMJ
Association of increased diabetes related complication and higher glycemic status in patients with type 2 diabetes mellitus (DM) has been well recognized. This cross sectional study was carried out to assess serum zinc (Zn) level and its relationship to glycemic status in type 2 DM patients and conducted in the Department of Physiology, Dhaka Medical College, Dhaka, Bangladesh from July 2014 to June 2015. Fifty (50) type 2 diabetic subjects with age ranging from 40 to 55 years were study group and fifty healthy subjects matched by ages and BMI were control group. Study population was chosen from Bangladesh Institute of Research for Diabetic Endocrine and Metabolic Disorders (BIRDEM) General Hospital, Dhaka, Bangladesh. Glycated hemoglobin (HbA1c) and fasting serum glucose (FSG) levels were estimated in the laboratory of the Department of Biochemistry, BIRDEM General Hospital, Dhaka, Bangladesh. Serum Zn level was estimated by flame atomic absorption spectrophotometry. For statistical analysis unpaired Student's 't' test was performed. In this study, mean serum zinc level was significantly (p<0.001) lower in patients than that of control group. On correlation analysis, serum Zn level showed significant negative correlation with FSG and HbA1C levels in type 2 diabetic patients. The results conclude that serum Zn level was reduced in DM which was higher with glycemic status of this disease.
Evaluation of Serum Zinc Status and Glycated Hemoglobin in Patients with Type-2 Diabetes Mellitus.
Israt S,Nessa A,Rahman H H,Sharmin A,Akter N,Dipa M I,Firoz S,Islam M F
Mymensingh medical journal : MMJ
Type-2 diabetes is the most common type of diabetes, accounting for about 90% of all diabetes. This study was done to assess the Serum Zinc status and Glycated Hemoglobin in type-2 diabetic patients in order to compare this parameter with healthy subjects. This analytical type of cross sectional study was carried out in the Department of Physiology, Mymensingh Medical College, Mymensingh, Bangladesh from July 2018 to June 2019. A total number of 140 subjects, age was ranged from 35-65 years were included in this study. Among them, seventy (70) type-2 diabetic patients were taken as study group (Group II) and seventy (70) age matched healthy subjects were taken as control group (Group I). Group I again subdivided into control group male (Group IA) and control group female (Group IB). Group II also subdivided into study group male (Group IIA) and study group female (Group IIB). Data were expressed as mean±SE and statistical significance of difference among the group was calculated by unpaired students' 't' test. Therefore, by this study we recommended that routine estimation of this parameter is important for prevention of complication related to diabetes for leading a healthy life.
Interrelationships among mediators of cellular zinc homeostasis in healthy and type 2 diabetes mellitus populations.
Chu Anna,Foster Meika,Hancock Dale,Petocz Peter,Samman Samir
Molecular nutrition & food research
SCOPE:The involvement of zinc in multiple physiological systems requires tight control of cellular zinc concentration. This study aims to explore the relationships among selected mediators of cellular zinc homeostasis in an apparently healthy (AH) population and a cohort with type 2 diabetes mellitus (T2DM). METHODS AND RESULTS:Baseline data of three trials forming two cohorts, AH (n = 70) and T2DM (n = 42), were used for multivariate analyses to identify groupings within ten zinc transporter and metallothionein (MT) gene expressions, stratified by health status. Multiple regression models were used to explore relationships among zinc transporter/MT groupings and plasma zinc. Gene expression of zinc transporters and MTs, with the exception of ZnT6, were significantly lower in the T2DM cohort (p < 0.01). Cluster analysis showed that the groupings of zinc transporters and MTs were largely similar between the two cohorts, with the exception for ZnT1 and ZIP7. Zinc transporters and MTs were significant determinants of plasma zinc (r = 0.48, p = 0.001) in the AH cohort, but not in the T2DM cohort. CONCLUSION:The current study suggests altered cellular zinc homeostasis in T2DM and supports the use of multiple zinc transporters and MTs groupings to further understand zinc homeostasis in health and T2DM.
Zinc and diabetes mellitus: understanding molecular mechanisms and clinical implications.
Ranasinghe Priyanga,Pigera Shehani,Galappatthy Priyadarshani,Katulanda Prasad,Constantine Godwin R
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
BACKGROUND:Diabetes mellitus is a leading cause of morbidity and mortality worldwide. Studies have shown that Zinc has numerous beneficial effects in both type-1 and type-2 diabetes. We aim to evaluate the literature on the mechanisms and molecular level effects of Zinc on glycaemic control, β-cell function, pathogenesis of diabetes and its complications. METHODS:A review of published studies reporting mechanisms of action of Zinc in diabetes was undertaken in PubMed and SciVerse Scopus medical databases using the following search terms in article title, abstract or keywords; ("Zinc" or "Zn") and ("mechanism" or "mechanism of action" or "action" or "effect" or "pathogenesis" or "pathology" or "physiology" or "metabolism") and ("diabetes" or "prediabetes" or "sugar" or "glucose" or "insulin"). RESULTS:The literature search identified the following number of articles in the two databases; PubMed (n = 1799) and SciVerse Scopus (n = 1879). After removing duplicates the total number of articles included in the present review is 111. Our results show that Zinc plays an important role in β-cell function, insulin action, glucose homeostasis and the pathogenesis of diabetes and its complications. CONCLUSION:Numerous in-vitro and in-vivo studies have shown that Zinc has beneficial effects in both type-1 and type-2 diabetes. However further randomized double-blinded placebo-controlled clinical trials conducted for an adequate duration, are required to establish therapeutic safety in humans.